Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UK Cost Agency Says No To Novartis AG's Blood Cancer Drug Jakavi-Reuters


Tuesday, 12 Feb 2013 07:01pm EST 

Reuters reported that A new drug from Novartis AG for myelofibrosis, a rare blood cancer, is not worth using on the state health service, Britain's healthcare cost watchdog said. The National Institute for Health and Clinical Excellence (NICE) said it had issued new draft guidance not recommending Jakavi because it could not be considered a cost-effective use of resources. 

Company Quote

91.55
0.35 +0.38%
11:30am EST